Search research articles
Contact Us
Filters
Showing results (31-40 of 46) with videos related to
Page
of 5
Sort By:
Antimicrobial Agents and Chemotherapy
|
August 7, 2015
Multicenter, Double-Blind, Randomized, Phase 2 Study Evaluating the Novel Antibiotic Cadazolid in Patients with Clostridium difficile Infection
Thomas Louie, Carl Erik Nord, George H Talbot, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
August 11, 2010
Integrated analysis of CANVAS 1 and 2: phase 3, multicenter, randomized, double-blind studies to evaluate the safety and efficacy of ceftaroline versus vancomycin plus aztreonam in complicated skin and skin-structure infection
G Ralph Corey, Mark Wilcox, George H Talbot, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
November 12, 2010
Integrated analysis of FOCUS 1 and FOCUS 2: randomized, doubled-blinded, multicenter phase 3 trials of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in patients with community-acquired pneumonia
Thomas M File, Donald E Low, Paul B Eckburg, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
October 12, 2017
Progress in the Fight Against Multidrug-Resistant Bacteria 2005-2016: Modern Noninferiority Trial Designs Enable Antibiotic Development in Advance of Epidemic Bacterial Resistance
John H Rex, George H Talbot, Mark J Goldberger, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
November 28, 2008
Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America
Helen W Boucher, George H Talbot, John S Bradley, et al.
The Journal of Antimicrobial Chemotherapy
|
April 13, 2011
FOCUS 2: a randomized, double-blinded, multicentre, Phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia
Donald E Low, Thomas M File, Paul B Eckburg, et al.
The Journal of Antimicrobial Chemotherapy
|
April 13, 2011
FOCUS 1: a randomized, double-blinded, multicentre, Phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia
Thomas M File, Donald E Low, Paul B Eckburg, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
April 20, 2013
10 x '20 Progress--development of new drugs active against gram-negative bacilli: an update from the Infectious Diseases Society of America
Helen W Boucher, George H Talbot, Daniel K Benjamin, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
February 5, 2019
The Infectious Diseases Society of America's 10 × '20 Initiative (10 New Systemic Antibacterial Agents US Food and Drug Administration Approved by 2020): Is 20 × '20 a Possibility?
George H Talbot, Amanda Jezek, Barbara E Murray, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
February 6, 2019
Efficacy and Safety of Intravenous-to-oral Lefamulin, a Pleuromutilin Antibiotic, for the Treatment of Community-acquired Bacterial Pneumonia: The Phase III Lefamulin Evaluation Against Pneumonia (LEAP 1) Trial
Thomas M File, Lisa Goldberg, Anita Das, et al.
Page
of 5
Search research articles
Search
Showing results (31-40 of 46) with videos related to
Sort By:
Page
of 5
Antimicrobial Agents and Chemotherapy
|
August 7, 2015
Multicenter, Double-Blind, Randomized, Phase 2 Study Evaluating the Novel Antibiotic Cadazolid in Patients with Clostridium difficile Infection
Thomas Louie, Carl Erik Nord, George H Talbot, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
August 11, 2010
Integrated analysis of CANVAS 1 and 2: phase 3, multicenter, randomized, double-blind studies to evaluate the safety and efficacy of ceftaroline versus vancomycin plus aztreonam in complicated skin and skin-structure infection
G Ralph Corey, Mark Wilcox, George H Talbot, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
November 12, 2010
Integrated analysis of FOCUS 1 and FOCUS 2: randomized, doubled-blinded, multicenter phase 3 trials of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in patients with community-acquired pneumonia
Thomas M File, Donald E Low, Paul B Eckburg, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
October 12, 2017
Progress in the Fight Against Multidrug-Resistant Bacteria 2005-2016: Modern Noninferiority Trial Designs Enable Antibiotic Development in Advance of Epidemic Bacterial Resistance
John H Rex, George H Talbot, Mark J Goldberger, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
November 28, 2008
Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America
Helen W Boucher, George H Talbot, John S Bradley, et al.
The Journal of Antimicrobial Chemotherapy
|
April 13, 2011
FOCUS 2: a randomized, double-blinded, multicentre, Phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia
Donald E Low, Thomas M File, Paul B Eckburg, et al.
The Journal of Antimicrobial Chemotherapy
|
April 13, 2011
FOCUS 1: a randomized, double-blinded, multicentre, Phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia
Thomas M File, Donald E Low, Paul B Eckburg, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
April 20, 2013
10 x '20 Progress--development of new drugs active against gram-negative bacilli: an update from the Infectious Diseases Society of America
Helen W Boucher, George H Talbot, Daniel K Benjamin, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
February 5, 2019
The Infectious Diseases Society of America's 10 × '20 Initiative (10 New Systemic Antibacterial Agents US Food and Drug Administration Approved by 2020): Is 20 × '20 a Possibility?
George H Talbot, Amanda Jezek, Barbara E Murray, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
February 6, 2019
Efficacy and Safety of Intravenous-to-oral Lefamulin, a Pleuromutilin Antibiotic, for the Treatment of Community-acquired Bacterial Pneumonia: The Phase III Lefamulin Evaluation Against Pneumonia (LEAP 1) Trial
Thomas M File, Lisa Goldberg, Anita Das, et al.
Page
of 5